The CSS (for all stage) in the adrenal sparing group was 84.3% compared with 74.9% in the non-adrenal sparing group (ASrN vs.
In this observational study in patients treated primarily with either ASRN or NASRN, with a 13-year follow-up, ASRN was associated with better survival than NASRN among patients with non-metastatic clear cell RCC.
(14) This may be a possible explanation of OS benefit in ASRN in our study.
Therefore, along with current evidence regarding survival benefits, ASRN should be performed unless contra-indicated.
Accepting the fact that a prospective randomized trial is impractical in this scenario, we found that our observational study with a 13-year follow-up suggests that ASRN leads to better survival than NASRN.